Objective responses and survival outcomes by grade 3-4 neutropenia in refractory metastatic colorectal cancer treated with trifluridine/tipiracil: Real-world evidence from the ReTrITA study.

Signorelli, C.; Basso, M.; Calegari, M.; Passardi, A.; Gallio, Chiara; Angotti, L.; Zurlo, I.; Dell'Aquila, Emanuela; Gemma, D.; Corsi, D.; Emiliani, A.; Arrivi, G.; Zoratto, F.; Santamaria, Fiorenza; Dettori, M.; Cosimati, A.; Saltarelli, R.; Minelli, A.; Lucci-Cordisco, Emanuela; Chilelli, M.

doi:10.1200/jco.2026.44.16_suppl.e15611

Public

Objective responses and survival outcomes by grade 3-4 neutropenia in refractory metastatic colorectal cancer treated with trifluridine/tipiracil: Real-world evidence from the ReTrITA study.

Shared by NobleBlocks on Jun 1, 2026 • 12:00 AM UTC

Authors:

C. Signorelli

M. Basso

M. Calegari

Abstract

e15611 Background: In refractory metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (T), treatment-related neutropenia has been associated with improved survival. Whether this benefit is linked to objective response patterns in real-world practice remains unclear. This s...

Discussions